secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001104659-25-118940
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix to submit AXPAXLI NDA based on SOL-1 year 1 data after FDA flexibility signal
--------------------------------------------------------------------------------

- FDA signals may allow single pivotal trial for AXPAXLI in wet AMD, changing prior two-trial requirement.
- Ocular Therapeutix now plans to submit NDA based on year 1 data from SOL-1 Phase 3 trial.
- Top-line year 1 data from SOL-1 expected in Q1 2026.
- Company will engage with FDA on regulatory pathway for AXPAXLI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925118940/0001104659-25-118940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925118940/tm2532882d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-118940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer